Multicenter clinical trials of in-vivo fluorescence: are the measurements equivalent?

Brian M. Pikkula; Dan Serachitopol; Calum MacAulay; Nicholas MacKinnon; Jong Soo Lee; Dennis Cox; E. Neely Atkinson; Michele Follen; Rebecca Richards-Kortum

doi:10.1117/12.700765

7 February 2007 Multicenter clinical trials of in vivo fluorescence: are the measurements equivalent?

Brian M. Pikkula, Dan Serachitopol, Calum MacAulay, Nicholas MacKinnon, Jong Soo Lee, Dennis Cox, E. Neely Atkinson, Michele Follen, Rebecca Richards-Kortum

Author Affiliations +

Proceedings Volume 6430, Advanced Biomedical and Clinical Diagnostic Systems V; 64301Q (2007) https://doi.org/10.1117/12.700765
Event: SPIE BiOS, 2007, San Jose, California, United States

Abstract

With the development of fluorescence spectroscopy, multicenter clinical trials are becoming more common both in the academic and commercial arenas. To ensure the quality of quantitative and device independent results, standardization of the tissue spectra is essential for the comparison of data from various groups. An added concern is the potential degradation of instrumentation during a trial which may affect the instrument's ability to accurately represent the tissue spectra. Our group has recently completed a Phase II clinical trial for the detection of cervical neoplasia using two different generations of spectroscopic devices at multiple sites. Both positive and negative optical standards were used to calibrate the tissue spectra as well as aid in the diagnosis of potential instrumentation problems during the trial. We have also conducted a cross validation study of fiber optic probes, spectroscopic devices, and optical standards for the latest generation of devices. The spectroscopic data of optical standards were analyzed for both the clinical trial and cross validation studies. Results demonstrated perceptible differences in optical standards data between the two generations of spectroscopy devices in the clinical trial, as well as the cross validation study with multiple devices of the same generation. Although the spectra were unexpectedly different, tissue spectra measured with the different systems can be empirically corrected by use of the various optical standards. Device performance during the clinical trial also was a concern; however, with the use of optical calibration standards, instrumentation problems were easily identified. To eliminate the problems associated with instrumentation, we have recently developed real-time quality assurance software to assess the optical calibration standards immediately after acquisition.

Citation Download Citation

Brian M. Pikkula, Dan Serachitopol, Calum MacAulay, Nicholas MacKinnon, Jong Soo Lee, Dennis Cox, E. Neely Atkinson, Michele Follen, and Rebecca Richards-Kortum "Multicenter clinical trials of in vivo fluorescence: are the measurements equivalent?", Proc. SPIE 6430, Advanced Biomedical and Clinical Diagnostic Systems V, 64301Q (7 February 2007); https://doi.org/10.1117/12.700765

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available